European Lung Cancer Congress 2019: A Multidisciplinary Approach to Fight Lung Cancer
Participants from across the world will meet in Geneva to learn about and discuss the latest research in the field of lung cancer.
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Participants from across the world will meet in Geneva to learn about and discuss the latest research in the field of lung cancer.
A new method of determining the sequence of molecules in DNA can be used to detect small fragments of cancerous genetic material in blood samples from lung cancer patients with a high degree of accuracy.
Françoise Mornex is first female recipient of Heine H. Hansen Award
The proportion of early-stage drug trials tackling the biggest cancer killers has declined sharply since the early 1990s as less common tumour types receive increasing attention, according to new research to be presented during the International Congress on Targeted Anticancer Therapies (TAT) 2019
The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, is pleased to announce the TAT (Targeted Anticancer Therapies) International Congress 2019
The TAT 2019 Honorary Award for cancer drug development has been given to Dr Geoffrey Shapiro for his leadership in developmental therapeutics, particularly in solid tumours
Anticancer vaccines have gained a new lease of life with techniques to personalise them to individual patients. Cutting edge developments in this re-energised field were revealed at the ESMO Immuno-Oncology Congress in Geneva, Switzerland.
First line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial presented at the ESMO Immuno-Oncology Congress.
New technologies in immuno-oncology that are set to benefit many more patients with cancer are being showcased at the ESMO Immuno-Oncology Congress, to be held 13-16 December in Geneva, Switzerland
Researchers predict that death rates from cancer will fall in 2018 in Australasian countries and in Russia. However, a greater proportion of the population will die in Russia from the disease than in any of the other countries, mainly because of the large numbers of men who still smoke.
ESMO is pleased to announce the ESMO Immuno-Oncology 2018 Congress, a dedicated platform in Europe to keep professionals up to date with the most recent and significant developments in this rapidly evolving field.
Rare cancers inherently make it difficult to collect data, build clinical expertise and treat affected patients – challenges which are best addressed through collaboration in international networks.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.